DESTINY-Breast03
2L HER2+ mBC
T-DXd
DESTINY-Breast05
Adjuvant HER2+ BC
T-DXd
DESTINY-Breast06
HR+/HER2-low mBC
T-DXd
DESTINY-Breast09
1L HER2+ mBC
T-DXd + Pertuzumab
EMBER-3
ER+/HER2- advanced BC
Imlunestrant
EMERALD
HR+/HER2- mBC (ESR1m)
Elacestrant
EVERA
ER+/HER2- mBC
Giredestrant + Everolimus
GeparDouze
TNBC neoadjuvant
Atezolizumab + chemo
HER2CLIMB-05
HER2+ mBC brain mets
Tucatinib
I-SPY 2.2
Neoadjuvant platform
Multiple agents
INAVO120
PIK3CA+ HR+/HER2- mBC
Inavolisib
INNOVATION
HER2+ gastric/breast
Trastuzumab + chemo
KEYNOTE-522
Neoadjuvant TNBC
Pembrolizumab + chemo
NATALEE
Adjuvant HR+/HER2- BC
Ribociclib
PADMA
HR+/HER2- mBC
CDK4/6 + endocrine
PATINA
HR+/HER2+ mBC
Palbociclib + anti-HER2
SERENA-6
HR+/HER2- mBC (ESR1m)
Camizestrant
SoltiVALENTINE
HR+/HER2- mBC
Novel
TROPION-Breast01
HR+/HER2- mBC
Datopotamab deruxtecan
TROPiCS-04
Pretreated mUC (post-platinum, post-IO)
Sacituzumab govitecan
VERITAC-2
HR+/HER2- mBC
Vepdegestrant
VIKTORIA-1
HR+/HER2- mBC
Camizestrant + Everolimus
ZEST
Early BC (ctDNA MRD)
Niraparib
lidERA
Adjuvant HR+/HER2- BC
Giredestrant
postMONARCH
HR+/HER2- post-CDK4/6 mBC
Abemaciclib rechallenge
ALASCCA
CRC (aspirin adjuvant)
Aspirin
BESPOKE
CRC (ctDNA MRD)
Signatera guided
BREAKWATER
BRAF V600E mCRC (1L)
Enco + Cetux + mFOLFOX6
COLLISION
Resectable colorectal liver mets
Surgery vs ablation
COMMIT
1L dMMR/MSI-H mCRC
Atezo + FOLFOX + bev
CRITICS-II
Resectable gastric (preoperative)
CT vs CT+CRT vs CRT
CodeBreaK 300
KRAS G12C mCRC
Sotorasib + panitumumab
DESTINY-Gastric04
2L HER2+ gastric/GEJ
T-DXd
DYNAMIC-III
Stage III colon (ctDNA-guided adj)
ctDNA strategy
ESOPEC
Resectable esophageal adeno
FLOT vs CROSS
HERIZON-GEA-01
1L HER2+ gastric/GEJ
Zanidatamab + chemo
ILUSTRO
CLDN18.2+ gastric/GEJ
Zolbetuximab triplet
KEYNOTE-937
Adjuvant HCC
Pembrolizumab
PANGEA-2
HER2+ gastric/GEJ
Targeted-platform
TRANSMET
Unresectable colorectal liver mets
Liver transplant
CLEAR
1L advanced RCC
Lenvatinib + Pembro
CheckMate-274
Adjuvant high-risk MIUC
Nivolumab
CheckMate-8HW
MSI-H/dMMR mCRC
Nivo + Ipi
CheckMate-901
1L mUC cisplatin-eligible
Nivo + gem/cis
CheckMate-9DW
1L uHCC
Nivo + Ipi
CheckMate-9ER
1L advanced RCC
Nivo + Cabozantinib
EV-302
1L mUC bladder
Enfortumab + Pembro
KEYNOTE-361
1L mUC bladder
Pembro ± chemo
KEYNOTE-B15
Perioperative cis-eligible MIBC
EV + Pembro
LITESPARK-011
Post-IO advanced ccRCC
Belzutifan + Lenvatinib
LITESPARK-022
Adjuvant ccRCC post-nephrectomy
Belzutifan + Pembro
LiteSpark-003
Advanced ccRCC
Belzutifan
NIAGARA
Perioperative MIBC
Durvalumab + GC
PEACE-3
mCRPC with bone mets
Enza + Radium-223
TalaPro-2
1L mCRPC (HRR+)
Talazoparib + Enza
TopGear
Resectable gastric
Preoperative chemoradiation
ADAURA
Adjuvant EGFR-mutant NSCLC
Osimertinib
ADEPPT
EGFR-mutant NSCLC (ELCC26)
Novel targeted
ADRIATIC
Limited-stage SCLC
Durvalumab
AEGEAN
Perioperative resectable NSCLC
Durvalumab + chemo
ALINA
Adjuvant ALK+ NSCLC
Alectinib
ASTEROID
NSCLC (ELCC26)
Novel targeted
BEAMION-LUNG-1
HER2-mutant NSCLC
Zongertinib
BECOME
NSCLC (ELCC26)
Novel targeted
CHRYSALIS-2
EGFR-mutant NSCLC (post-osimertinib)
Ami + Laz
CROWN
1L ALK+ NSCLC
Lorlatinib
CheckMate-77T
Perioperative NSCLC
Nivolumab + chemo
DELLPHI-304
SCLC
Tarlatamab
EVOKE-01
Post-platinum NSCLC
Sacituzumab govitecan
FLAURA
1L EGFR-mutant NSCLC
Osimertinib
FLAURA2
1L EGFR-mutant NSCLC
Osimertinib + chemo
HARMONi
EGFR-mutant NSCLC
Ivonescimab
HARMONi-2
1L PD-L1+ NSCLC
Ivonescimab
HARMONi-A
EGFR-mutant NSCLC (Asia)
Ivonescimab
KEYNOTE-671
Perioperative NSCLC
Pembrolizumab + chemo
KRYSTAL-12
KRAS G12C NSCLC
Adagrasib
LAURA
Post-CRT stage III EGFR+ NSCLC
Osimertinib
LUNAR
Post-platinum NSCLC (TTFields)
TTFields + SoC
MARIPOSA
1L EGFR-mutant NSCLC
Amivantamab + Lazertinib
METIS
NSCLC brain mets (TTFields)
TTFields
OptiTROP-Lung03
NSCLC (ELCC26)
Sacituzumab tirumotecan
PALOMA-3
EGFR+ NSCLC (subcutaneous)
Amivantamab SC
PRESERVE-003
Perioperative NSCLC (ELCC26)
Novel targeted
SKYSCRAPER-01
1L PD-L1+ NSCLC
Tiragolumab + atezo
TOP Study
NSCLC (ELCC26)
Biomarker-driven
i-TIMES
NSCLC (ELCC26)
Novel targeted
AQUILA
Smoldering MM
Daratumumab
AURIGA
Post-transplant maintenance
Daratumumab + Len
CAR-PRISM
High-risk NDMM
CAR-T front-line
CARTITUDE-2
1-3 prior lines
Cilta-cel
CARTITUDE-4
Len-refractory MM
Cilta-cel
CARTITUDE-6
NDMM transplant-eligible
Cilta-cel front-line
CASSIOPEIA
Transplant-eligible NDMM
Dara-VTd
CEPHEUS
Transplant-ineligible NDMM
Dara-VRd
DREAMM-7
RRMM post-1 line
Belantamab + Vd
DREAMM-8
RRMM (len-exposed)
Belantamab + Pd
DREAMM-9
NDMM transplant-ineligible
Belantamab + VRd
GMMG-HD6
NDMM transplant-eligible
Elo + VRd
GMMG-HD7
NDMM transplant-eligible
Isa-VRd induction
IsKia
Transplant-eligible NDMM
Isa-KRd
KarMMa-3
RRMM (2-4 prior lines)
Ide-cel
MajesTEC-4
Post-transplant maintenance
Teclistamab
MajesTEC-5
NDMM transplant-eligible
Tec + DRd
PERSEUS
Transplant-eligible NDMM
D-VRd
iMMagine-1
RRMM
Anito-cel (BCMA CAR-T)
3082CL0101
Solid tumors
Novel agent
ABRAVE
Oncology
-
ACCELERATE
Oncology
-
ANDROMEDA
Oncology
-
ARMANI
Oncology
-
BLB01D1
Solid tumors
BL-B01D1 ADC
CABINET
Neuroendocrine tumors
Cabozantinib
CALYPSO
Oncology
-
EUROPA
Oncology
-
EXALT-3
Oncology
Functional precision
JS001-SC
Oncology
Toripalimab SC
KANDLELIT-001
Solid tumors
Novel agent
LATIFY
Oncology
-
NCT05879978
Solid tumors
Novel agent
NORTHSTAR
Oncology
-
SACItuzumab-IO
Oncology
Sacituzumab + IO
SUPREMO
Oncology
-
StarterNET
NETs
-
YL202
Solid tumors
Novel ADC